Misplaced Pages

Indivior

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Specialty pharmaceuticals company

Indivior
Company typePublic company
Traded asLSE: INDV
IndustryPharmaceutics
Founded1994
HeadquartersRichmond, Virginia
Key peopleGraham Hetherington, Chairman
Mark Crossley, CEO
ProductsSubutex/Subuxone/Sublocade
RevenueIncrease $1,093 million (2022)
Operating incomeIncrease $(4) million (2022)
Net incomeIncrease $2 million (2023)
Websitewww.indivior.com/

Indivior is a specialty pharmaceuticals business. Established as a division of Reckitt Benckiser in 1994 and demerged from that company in December 2014, the company has been fined for false marketing claims about the safety of its drug, Suboxone. It is listed on the London Stock Exchange and on the NASDAQ Global Select Market.

History

The company was established as the Buprenorphine division of Reckitt Benckiser in 1994. In December 2014, Reckitt Benckiser spun off its specialty pharmaceuticals business into a separate company named Indivior. By February 2015, the company was capitalised at £2.3 billion (US$3.1 billion) on the London Stock Exchange.

In 2019, Indivior was indicted over claims that it had made false marketing claims about the safety of its drug, Suboxone, and had concocted a scheme to direct patients towards doctors who were likely to prescribe Suboxone. Reckitt Benckiser has settled with the Justice Department to pay $1.4 billion to resolve a U.S. Federal investigation into sales and marketing of opioid addiction treatment.

In July 2020, Indivior Solutions, Indivior Inc., and Indivior PLC agreed to pay $600 million to resolve liability related to false marketing of Suboxone to MassHealth for use by patients with children under the age of six years old. Additionally, Indivior Solutions Inc pleaded guilty to one-count of felony information.

In November 2022, it was announced Indivior had acquired the Santa Monica-headquartered, NASDAQ-listed biopharmaceutical company, Opiant.

In July 2023 Indivior paid $20.4 million to C4X Discovery for the full rights to the orexin-1 receptor antagonist being developed for substance use disorder. Indivior had already made an upfront payment of $10 million in 2018 and pledged milestone payments of up to $284 million. Under the new agreement C4X Discovery waived any rights to further payment.

In May 2024, the company confirmed that it would transfer its primary share listing to the U.S.

Operations

The company's main products are Sublocade, Subutex and its Naloxone-combined preparation Suboxone, both substitution products for opioid addiction. Other products include remedies for cocaine and opioid analgesic overdose and treatment for alcohol dependence: the company claims this to be the largest pipeline of addiction drugs in the world.

  • Suboxone sublingual film Suboxone sublingual film

References

  1. ^ "Annual Results 2023" (PDF). Indivior. Retrieved 22 February 2023.
  2. ^ "Indivior faces generic challenge". Investors Chronicle. 2 February 2015. Retrieved 22 March 2015.
  3. "RB complete demerger of Indivior - RB". RB. 23 December 2014. Archived from the original on 29 March 2015. Retrieved 21 March 2015.
  4. "Is Indivior PLC The Perfect Partner For AstraZeneca plc in Your Portfolio?". Retrieved 22 March 2015.
  5. "Reckitt to Pay $1.4 Billion to End Long-Running Indivior Probes". The New York Times. 11 July 2019. ISSN 0362-4331. Retrieved 11 July 2019.
  6. "Reckitt to pay $1.4 billion to end long-running Indivior probes". Wall Street Report. Retrieved 11 July 2019.
  7. "Reckitt to pay $1.4 billion to end long-running Indivior probes". Reuters. 11 July 2019. Retrieved 11 July 2019.
  8. "Indivior Solutions Pleads Guilty to Felony Charge as Part of DOJ's Largest Opioid Resolution". uspsoig.gov. United States Postal Service Office of Inspector General. 24 July 2020. Retrieved 7 September 2020. Indivior Solutions today pleaded guilty to a one-count felony information and, together with its parent companies Indivior Inc. and Indivior PLC, agreed to pay a total of $600 million to resolve criminal and civil liability associated with the marketing of the opioid-addiction-treatment drug Suboxone. All other charges against Indivior were dismissed. Together with a $1.4 billion resolution with Indivior's former parent, Reckitt Benckiser Group PLC (RB Group), announced in 2019, and a plea agreement with Indivior plc's former CEO, Shaun Thaxter, announced last month, the total resolution relating to the marketing of Suboxone is more than $2 billion.
  9. Media, Insider. "Indivior to acquire US biopharmaceutical company". Insider Media Ltd. Retrieved 15 November 2022.
  10. Waldron, James (1 August 2023). "C4X sells full rights for substance use disorder drug to Indivior as part of refocus". Fierce Biotech. Retrieved 28 September 2023.
  11. "Indivior Shareholders Approve Main Listing Switch to U.S." Market Watch. 23 May 2024. Retrieved 21 June 2024.
  12. "Drug firm Indivior plans to move primary listing to US in snub to London". The Guardian. 22 February 2024. Retrieved 21 June 2024.
  13. "RB spin-out Indivior says addiction pipeline will deliver". Pharmaphorum. 21 November 2014. Retrieved 22 March 2015.

External links

Categories: